Effect of Chronic Pretreatment of Angiotensin-Converting Receptor Blocker on No-Reflow Phenomenon in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Cardiovascular Therapeutics

Volumn 31, Issue 3, 2013, Pages

  Hu, Tao ^a   Wang, Hai Chang ^a   Wang, Ru Tao ^a   Lv, An Lin ^a   Luan, Rong Hua ^a   Li, Cheng Xiang ^a   Cheng, He Xiang ^a   Xia, Cheng Hai ^a   Tao, Ling ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute Myocardial Infarction; Angiotensin receptor blockers; Percutaneous Coronary Intervention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ADULT; ANGIOGRAPHY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR STENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PREDICTOR VARIABLE; PREMEDICATION; PRIORITY JOURNAL;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84876474940     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2012.00314.x     Document Type: Article

References (16)

1. Cantor WJ, Fitchett D, Borgundvaag B Ducas J, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Me 2009;360:2705-2718.
2. Olszowska M, Tracz W, Kostkiewicz M, Podolec P. Predictive factors of myocardial reperfusion in patients with anterior wall acute myocardial infarction. Cardiol J 2008;15:57-62.
3. Zhao JL, Yang YJ, Pei WD, Sun YH, Chen JL. The effect of statins on the no-reflow phenomenon: An observational study in patients with hyperglycemia before primary angioplasty. Am J Cardiovasc Drugs 2009;9:81-89.
4. Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care 2009;11:69-76.
5. Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag 2009;5:21-29.
6. Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol 2008;13:121-128.
7. Muller O, Windecker S, Cuisset T, et al. Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations. EuroIntervention 2008;4:181-183.
8. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008;72:950-957.
9. Fischell TA. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol 2008;20:374-379.
10. Lee KW, Norell MS. Management of 'no-reflow' complicating reperfusion therapy. Acute Card Care 2008;10:5-14.
11. Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 2. Prev Cardiol 2008;11:215-222.
12. Matsuoka H. Large clinical trials of ARB in Japan and its reflection to new guidelines. Nippon Rinsho 2009;67:69-74.
13. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Euro Heart J 2008;29:2909-2945.
14. Kim-Mitsuyama S. Pharmacological characteristics of ARB and potential strategy to develop novel ARB. Nippon Rinsho 2009;67:812-818.
15. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: Focus on olmesartan medoxomil. Vasc Health Risk Manag 2009;5:301-314.
16. Meneveau N, Séronde MF, Descotes-Genon V Dutheil J, et al. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: A matched comparison in acute myocardial infarction patients. Clin Res Cardiol 2009;98:257-264.